was ~2x power to classify pathogenic variants. Affectedsonly analysis resulted in virtually no power to correctly classify benign variants and reduced power to classify pathogenic variants. These results can be used to guide recruitment efforts to classify rare and private VUS.
Introduction
Genetic testing for diagnosis and risk assessment is becoming standard of care for a wide variety of inherited diseases. Next generation sequencing panels and exome/genome sequencing often identify extremely rare variants of uncertain significance (VUS) in known pathogenic genes [1] . These rare VUS may be private to a single family, precluding the ability to assess sufficient independent samples for case-control association testing [2] . As the number of patients receiving clinical or research sequencing, and the number of genes sequenced per patient, increases, it is expected that the number of extremely rare VUS will dramatically increase [3] . Challenges in assessing pathogenicity of these variants will undoubtedly continue for decades.
The American College of Medical Genetics and Genomics (ACMG) and Association of Molecular Pathology (AMP) proposed recommendations for clinical variant classification [4] . Although these recommendations are nuanced, in general, a variant has strong or very strong evidence of pathogenicity if it is rare among all populations and any of the following are true: it is a null variant in a gene known to have other pathogenic null variants, there are multiple in silico and in vitro pieces of evidence supporting pathogenicity, or the prevalence 1 3 of the variant is significantly higher in affected individuals than in unaffected individuals. Accordingly, rare and family-specific VUS, which have arisen in the last several 100 years, will have, at most, weak evidence for pathogenicity as they will be absent in population databases and are unlikely to have extensive functional data. Beyond frequency, the only ACMG-AMP specified data likely to be available for private VUS is from in silico computational algorithms or in vitro studies of protein levels and activity.
Family studies are a source of independent information potentially available for all types of VUS that can aid their classification. Simple methods of counting affected heterozygotes, or the meioses connecting them, have been proposed, and may be ideal for completely penetrant traits [5] . However, meiosis-counting methods do not fully account for incomplete penetrance, variable expressivity, variable age of onset, or phenocopies. Despite these challenges, meiosis-counting methods are commonly used and often misused [1] . Alternatively, as has been proposed by the International Society for Gastrointestinal Hereditary Tumors (InSiGHT), family-based co-segregation analysis methods can be applied in the situation of rare VUS in genes known to be associated with risk phenotypes under a dominant mode of inheritance, adjusting for age of onset, sex, and the population based prevalence, among other risk factors [6] [7] [8] . Furthermore, the quantitative result from co-segregation can be validated and combined with other quantitative data, creating robust evidence to classify VUS [4, 8, 9] .
Most clinical laboratories that offer genetic sequencing also offer family studies to at least a subset of families with a VUS [10] . However, policies and practices vary between clinical laboratories and segregation studies may be preferentially offered where initial family structure suggests the variant could be pathogenic [10, 11] . Yet, few laboratories have reported on success rates for family studies. This may be because the timeline for classification is typically many years, and may be indefinite, particularly for VUS that are private to one family [2, 12, 13] . Furthermore, the types of relatives and family structures needed to yield strong classification evidence is not well defined. Previous research on the power of family segregation evaluated uniform, generic families, without taking into consideration population demographics and family structure for precise co-segregation analysis [2, 14, 15] . Power of typical linkage analysis, where the goal is to identify a polymorphic region of the genome in linkage with disease, increases with the number of informative meisoses (i.e., parental alleles can be definitively assigned to an offspring) [16, 17] . However, little is known about how family structure influences variant classification when the gene is a priori known to be causal for the phenotype and the variant is extremely rare.
Here we report the results of modeling population demographics and family structure to determine the potential power of linkage analysis in single extended families to generate strong evidence for classification of VUS using Lynch syndrome (MIM: 120435) and breast/ovarian cancer (MIM: 604370 and 612555) penetrance models. Lynch syndrome and breast/ovarian cancer are among the most common cancers in the United States and China, making them ideal candidates [18, 19] . We focused on the most common genes underlying these disorders [MLH1 (MIM: 120436)/MSH2 (MIM: 609309); BRCA1 (MIM: 120436) and BRCA2 (MIM: 600185)] as they are frequently the first genes sequenced in the clinic. In addition, we evaluated the kinds of relatives that can increase power, so that efforts at recruitment of relatives can lead to higher gains in power.
Materials and methods

Simulated pedigrees
We generated pedigrees designed to mimic historical demographic data from China (CHI) and the United States (USA) using the R package CoSeg (see "Web resources" section). We used reports from census and other population records to inform changes in family structure through the twentieth century and into the early twenty-first century, including the US Census Bureau, gapminder.org, the World Bank, and academic texts [20] [21] [22] [23] [24] [25] . Simulation models used estimated distributions from these sources for age at marriage, fertility, and mortality (Supplemental Table 1 ).
Simulated families were seeded with a proband whose age is sampled from a skewed Normal distribution [mean (µ) = 51.5 years, standard deviation (σ) = 10, skew (ξ) = 0.8], in order to mirror the age distribution of individuals seeking hereditary cancer testing at the University of Washington. We created realistically aged founder ancestors two, three, or four generations back from this proband creating 1000 each of small, medium and large families, respectively.
Marriage age was modeled using a positively skewed distribution around the reported median with σ = 2.5 and ξ = 1.5 for each decade between 1900 and 2000, and one estimated median for any marriage in the nineteenth century. We simulated a spouse, descendants, and death year of the seed individual based on the demographic data specific to that individual's nationality, birth year, and sex. Simulated death ages were generated from data on average survival of 20-year-olds with a slight negative skew (σ = 1/6, ξ = 0.8). Simulated number of offspring followed a Poisson distribution with mean (λ) set at fertility minus child mortality. Probability of female offspring and probability of a child inheriting the VUS from a heterozygous parent were both set at 0.5. Functions for pedigree simulation and default parameters are documented and publicly available in the CoSeg package.
Simulated genotypes and phenotypes
After each pedigree was simulated, genotypes and phenotypes were simulated. Genotypes were simulated from the founder ancestor down the pedigree, while ensuring the proband inherited the VUS from the founder. We assumed all variants would be extremely rare so that simulated families could trace inheritance of a single VUS through their family.
Given each genotype, phenotypes at all individuals were simulated using sex and age specific penetrance, assuming a dominant mode of inheritance and published penetrance models [26, 27] . Phenotypes included Lynch syndrome associated cancers (colon, endometrial or minor Lynch tumor defined as grouped small bowel, stomach, ovary, and urinary tract cancers) due to MLH1 or MSH2 and breast or ovarian cancer due to either BRCA1 or BRCA2. As the penetrance model for BRCA1 differs from that of BRCA2, separate simulations were performed for each of these genes. Phenotypes for each of these cancers were also simulated assuming the variant was benign, using SEER data for population-based penetrance of disease [19] . Finally, to ensure that the pedigree size was not too large for the analysis method (i.e., N < 600), low information individuals were pruned from the pedigree. Low information individuals were defined to be any individual who was neither a first-degree relative of any heterozygous or affected individual, nor an individual who connected heterozygous or affected relatives in the pedigree, as they are unlikely be heterozygous for the VUS. Typically, low information individuals are not ascertained in the clinic or research setting, as they do not have the disease and genotypes of relatives usually make it clear that they do not have the variant of interest, (e.g., if the variant is known to be maternal, paternal relatives are not genotyped). In this way pruned simulated pedigrees are more similar to expected pedigrees.
Simulated missing data
In order to assess the effect of missing data, we simulated 8000 each small and large USA families for pathogenic MLH1/MSH2, pathogenic BRCA2, and the respective benign variants. After the pedigrees were simulated, genotype and phenotype data were removed at random for each individual, with probability 0.5. As before, low information individuals were pruned from the pedigrees.
Statistical analysis
We calculated a LOD score (LODadj), adjusted for the prior information that the proband is heterozygous for the VUS at a known pathogenic gene [28] . Briefly, the alternative hypothesis is that the VUS is in complete linkage disequilibrium (LD = 1) with a truly pathogenic variant segregating perfectly with the phenotype [recombination rate (θ) = 0]. The null hypothesis for this test is that the gene-specific VUS is not associated with increased risk of cancer (LD = 0, θ = ½). We used FASTLINK to calculate LODadj = LOD 3 + LOD 2 − (LOD 1 + LOD 4 ), where LOD i is calculated under one of the following conditions: LOD 1 : LD = 0, θ = ½, and all available genotypes are known.
LOD 2 : LD = 0, θ = ½, and only the proband genotype is known.
LOD 3 : LD = 1, θ = 0, and all available genotypes are known.
LOD 4 : LD = 1, θ = 0, and only the proband genotype is known.
Unless otherwise indicated, we assumed a VUS allele frequency of 0.001, as this is the overall frequency of pathogenic alleles in BRCA1 and is higher than the overall frequency of pathogenic alleles in BRCA2 or MLH1/MSH2. Furthermore, this higher allele frequency allows for the possibility that the VUS has entered the pedigree from someone other than the founder. We analyzed the data using an age and sex based step-wise approximation of the penetrance functions used to simulate the associated phenotype data when the VUS was pathogenic (Supplemental Tables 2, 3 and 4). The approximation breaks the continuous penetrance function into a step-wise function of cumulative risk for 10 year periods. For analysis of the benign VUS simulated data, we used the Lynch-specific penetrance matrix for the Lynch-associated phenotypes, and the BRCA1-specific penetrance for the breast/ovarian cancer families. Unless otherwise indicated, genotypes are known for live individuals, only.
Power and type I error
To calculate power, we compared LODadj to cutoffs for variant classification from the international agency for research on cancer (IARC) guidelines [29] : Pathogenic if LODadj ≥ 2, Likely Pathogenic if LODadj ≥ 1.3, Likely Benign if LODadj ≤ −1.3 and Benign if LODadj ≤ −2. It is important to note that according to ACMG guidelines there are currently no cutoffs that define the relative strength of evidence from segregation, and segregation alone cannot prove that a VUS is pathogenic. However, segregation scores above reasonable thresholds can be used as moderate or strong evidence when combined with in vitro, functional, or evolutionary conservation evidence to establish pathogenicity of a VUS [4] .
Linear model analysis
We used linear models to evaluate the effect and significance of multiple pedigree descriptors on LODadj for the large pedigrees. We chose to focus on the large pedigrees because they vary the most in information content and can give the most precise estimates of effect. As these pedigrees are unlikely to reflect those seen in the clinic, we also evaluated the pedigrees that had missing data in order to determine the effect of missingness on the significance of these descriptors. The descriptors of interest included those that can be calculated prior to genotyping individuals in the pedigree: number of affected individuals (N aff ), number of unaffected individuals (N unaff ), minimum age of onset (MAO), and degree of relatedness between the proband and the furthest affected relative (FAR). N aff , N unaff , and MAO were natural-log transformed. Since these descriptors are correlated, we performed step-wise analysis and evaluated the significance of interaction terms to determine the best model to explain the most variation in LODadj. We included the interaction terms if they were statistically significant at the 5% level in addition to the individual terms remaining significant in the presence of the interaction, also at the 5% level. Additionally, in order to estimate the value of genotyping unaffected individuals, we estimated the percent variation in LODadj explained by the natural log transformed number of unaffected individuals heterozygous for the VUS (N UH ), separately from the other variables, as it can only be calculated after genotyping.
Results
Simulated pedigrees
As expected, pedigree size increased with the number of generations, with the maximum size reaching into the midthousands (Supplemental Figs. 1 and 2 ; Table 1 ). Pruning away the low information individuals substantially reduced the pedigree sizes. Pruned pedigree sizes are larger under the CHI demographic model than under the USA demographic model due to the larger number of individuals in the CHI demography in earlier generations (Supplemental Fig. 3 ). Pruned pedigree sizes are larger for the Lynch syndrome model than for the breast/ovarian cancer model, due to low frequency of affected males heterozygous for the VUS in the BRCA1/2 pedigrees. Pedigrees with missing data were similarly sized to those with complete data, even after pruning. Additionally, the percent of pedigrees that had only one affected individual (i.e., the proband) decreases with increased number of generations (Tables 2,  3 ).
The percent of affected individuals that are heterozygous for the VUS decreases as pedigree size increases (Tables 2,  3 ). For the pedigrees segregating a pathogenic variant, this is due to larger pedigrees having a higher overall probability of observing an affected individual whose underlying cause is unrelated to the VUS. In simulations where the variant is causal, >46 and >51% of the affected individuals (not including the proband) were heterozygous for the VUS, for Lynch syndrome and breast/ovarian cancer, respectively. In simulations where the VUS is benign, <20% of the affected individuals, not including the proband, are heterozygous for the VUS, for both Lynch syndrome and breast/ovarian cancer.
Power and type I error
Overall, the pedigrees simulated with a pathogenic VUS from the CHI demographic have higher LODadj than the pedigrees from the USA demographic (Supplemental Fig. 4 ). This is likely due to the larger pedigree sizes from the CHI demographic. The power to detect moderate or strong evidence for pathogenicity is highest for BRCA1 followed by MLH1/MSH2, and then BRCA2 (Fig. 1,   Supplemental Fig. 4 , Supplemental Tables 5 and 6 ). The power and type I error are not affected by analysis with a smaller allele frequency (q = 10 −6 , data not shown) or doubling or halving the population based penetrance (data not shown). Larger pedigrees had more power as the proportion of pedigrees with only one affected individual (i.e., the proband) was smallest in this category. The presence of missing data affects the power, reducing by it by ~1/10 for the small families and ~1/3 for the large families (Supplemental Tables 5 and 6 ). This reduction is due to the even higher percentage of families with a single affected individual.
Overall, the power to assign a truly benign VUS as benign was ~2x higher than the power to assign a truly pathogenic VUS as pathogenic (Supplemental Fig. 4 ; Supplemental Tables 5 and 6 ). For example, the power for a pathogenic MLH1/MSH2 variant was 25% whereas the power for a benign MLH1/MSH2 variant was 53% for the large CHI families. For the families with missing data, the power to correctly classify a benign variant was ~6x higher. None of the families segregating a benign variant yielded evidence supporting variant pathogenicity (type I error for benign variants) regardless of pedigree sizes and types (Supplemental Fig. 4 ; Supplemental Tables 5 and 6 ). However, some families with simulated pathogenic variants (0-4.2%, depending on trait, pedigree size, and missingness) had LODadj < −2 (type I error for pathogenic variants); this "false negative" rate increased with pedigree size.
Linear model analysis
Step-wise linear model analysis indicated that N aff explained the most variation (21-38%) in LODadj for all traits, generally (Table 4) . N aff is positively associated with LODadj when the VUS is pathogenic and is negatively associated with LODadj when the VUS is benign. Moreover, our simulations indicate that at least 5, 3, and 4 (and typically many more) affected individuals are necessary to achieve a LODadj ≥ 2 for a VUS pathogenic for MLH1/MSH2, BRCA1 and BRCA2, respectively. The addition of FAR to the model explained slightly more variation in LODadj for both SEER traits (1-5%) and Lynch syndrome (7%). FAR is negatively associated with LODadj for both SEER traits (benign VUS) and is negatively associated with LODadj when the VUS is pathogenic for Lynch, only after adjusting for N aff . For both BRCA1 and BRCA2 the addition of MAO to the model explained slightly more variation (5-13%). MAO is negatively associated with LODadj when the VUS is pathogenic for either BRCA1 or BRCA2. The best model included the interaction terms, except for breast/ovarian cancer with a benign variant in the USA demographic. Results were similar for the large USA pedigrees with missing data, for all variants, as well as for the small USA pedigrees with missing data segregating a benign variant. In contrast, FAR explained slightly more variation on LODadj than N aff , for the small USA pedigrees with missing data, segregating a pathogenic variant. When considering all the pedigrees, FAR explained 14.7 and 15.5% of the variation in LODadj for MLH1/MSH2 and BRCA2 pathogenic variants, respectively. When considering the pedigrees with more than one affected individual, FAR explained 10.2 and 10.4% of LODadj, respectively. Furthermore, MAO and Naff additionally explain ~2 and 3% more of the variation, for the BRCA2 pathogenic variant (including interaction term) and the BRCA2 benign variant, respectively.
Genotyping unaffected individuals was crucial for correctly identifying benign variants. For families with a benign VUS, N UH explained more of the variance in LODadj (≥60%) than the corresponding best model using variables that are not dependent on genotype (≤37%) ( Tables 4,  5 ). Furthermore, affecteds-only linkage analysis resulted in much lower power (0.1 and 0.4% for Lynch syndrome and breast/ovarian cancers, respectively) to classify a benign variant correctly (Fig. 2) .
Discussion
We have shown how different parameters related to demographics of the United States and China influence power for classification of rare VUS in established cancer risk genes using family studies. Marriage age has increased and family size has decreased in both Chinese and American populations since the middle of the twentieth century. However, these changes have been more dramatic in the Chinese population. Family size is related to power, as expected, and currently families from the Chinese demographic have higher power than families from the United States demographic. This is likely due to the larger family size in the 1950s and 1960s in China, resulting in overall larger simulated pedigrees, with more affected individuals, and therefore more information. This could suggest that extending pedigrees to have the most distant possible founder heterozygous for the VUS would be advantageous. However, as pedigree size increases, the possibility of phenocopies or other risk alleles related to the same trait also increases, complicating the analysis. Moreover, the more distantly related an affected relative is to the proband, the more likely, that he/she will not be heterozygous for the VUS. Rather than focusing on recruiting distant relatives, initial recruitment efforts could concentrate on finding as many affected relatives as possible, regardless of the strength of their genetic relationship with the proband. We have shown that the power of single extended pedigrees to classify family specific VUS mostly depends on the number of affected individuals. This is most likely due to the high correlation between the number of affected individuals and the number of informative matings (i.e., where an informative meiosis is possible). This high correlation is explained as follows: (1) The only possible informative matings for these pedigrees involve a common homozygote with a heterozygote, as the VUS is extremely rare and (2) Most affected individuals are expected to be heterozygotes as the number of phenocopies are low. Therefore, most affected individuals represent at least one informative mating (the affected individual's parents) and possibly a second informative mating (the affected individual's mate). In contrast, results from the small families with missing data indicate that recruiting distantly related affected individuals may be crucial to the power. This is likely due to the lower number of affected individuals expected in this scenario.
In general, the degree of relationship to the farthest affected relative and the minimum age of onset in the pedigree, influences power to a lesser extent than the total number of affected individuals. For the pathogenic Lynch variants and both cancer type benign variants, the degree of relationship to the farthest affected relative influences power. This might indicate that efforts at finding distantly related affected individuals could be fruitful in the case when current family structure does not have power to classify a variant for a trait that has similar penetrance among both sexes. However, for the BRCA1/2 pathogenic variants, the minimum age of onset contributed more to the power. Lower ages of onset may also increase the number of informative matings in the pedigree. Interestingly, BRCA1 was first localized through the use of pedigrees with low ages onset of breast cancer [30] . This may be due to the fact that very few males have cancers due to BRCA1/2, so that only about half of heterozygotes have a non-negligible probability of developing cancer, potentially reducing the availability of distantly related affected heterozygotes. Furthermore, the penetrance for breast/ovarian cancer in females is higher than the penetrance for Lynch syndrome, indicating that the underlying penetrance does not explain why minimum age of onset explains so much of the variation in power. This might indicate that recruitment efforts and screening should focus on younger individuals when the trait under consideration has much higher penetrance among one sex.
Although the rationale for segregation analysis is to demonstrate that a variant is pathogenic, most VUS, absent any clinical or in vivo data on tumor samples, are expected to be benign [11, 12, 31] . In fact, the ability to classify variants as benign may be the most powerful use of co-segregation analysis [32] . We have shown that family analysis has more power to classify a benign variant than a pathogenic variant, when all live individuals are genotyped, regardless of phenotype. The number of unaffected heterozygotes explains the largest portion of variation in LODadj in this situation. Moreover, when only affected individuals are analyzed, the LOD score approach fails to correctly classify benign variants >99% of the time. This error is likely to be exacerbated when meiosis counting methods are used, possibly resulting in false evidence of pathogenicity [5] . Moreover, if strong quantitative evidence that a VUS is benign is reported to ClinVar, this could alleviate future emotional and financial costs when similar private variants are found in other families. Therefore, in addition to genotyping affected individuals, unaffected individuals who have a non-zero probability of being heterozygous for the VUS should also be genotyped. For example, if the proband's unaffected great-aunt is genotyped and does not have the VUS, then pursuing her offspring is not useful. However, if the unaffected great-aunt has the VUS, then she and her offspring, if genotyped, impart useful information. Identifying and recruiting both affected relatives and potentially heterozygous unaffected relatives requires substantial time and effort. Although only a small percent of the pedigrees with pathogenic variants contained moderate or strong evidence for pathogenicity, the quantitative results can be combined with other data for variant classification [8] . There is almost always quantitative in silico data that could be combined with quantitative segregation evidence, even if neither is independently conclusive. In some cases, in vitro assays may be available to test the effect of the VUS. These assays can provide independent evidence for or against pathogenicity; however, these data should be combined with caution, particularly with discrepant results. If the quantitative results from co-segregation analysis are in conflict with in vitro data, this may indicate that the in vitro assay does not capture the underlying cancer biology and perhaps further, or different, in vitro analysis is warranted [33, 34] .
Our results indicating which individuals are likely to contribute valuable information are for the large pedigrees as they are likely to provide the most accurate measure of effect size and significance for pedigree descriptors on the resulting LODadj. However, these pedigrees are much larger than those usually tested in the clinic setting. It is possible that the number of affected individuals has a smaller effect size in smaller families. However, we believe the trend is the same: the larger the number of affected individuals, the higher the power. Realistically, many individuals will not be genotyped and second hand knowledge of relatives' phenotypes may not be accurate in the clinic setting, or missing, resulting in less informative pedigrees. In this case, it may be prudent to ascertain distantly related affected individuals. Similarly, for small families with a trait in which penetrance is virtually zero for one sex, reducing the potential number of affected individuals, ascertaining distantly related affected individuals may have a larger effect on power. Another limitation of our study is that we used known age-and sex-based penetrances, which is unlikely to be the case for all variants. However, for many known pathogenic genes, there are multiple estimates of sex-and age-based penetrances available in the literature [26, 27, 35] . Furthermore, when most genotypes and phenotypes are known, small to moderate changes in the penetrance matrix had virtually no effect on the LOD score in our analysis.
We have presented simulation-based evidence to guide recruitment efforts for individuals considering family studies for VUS classification. Currently, there is little quantitative evidence from family segregation studies reported in ClinVar. We have shown that data from a single family can produce useful information, particularly for benign variants in large families, which could be added to ClinVar. Furthermore, new resources have made family studies more accessible to patients and genetics providers [10] and new statistical tools are available for quantitative family co-segregation analysis (see "Web resources"). We hope that these tools will encourage increased reporting of quantitative results from co-segregation analysis in families and that future ACMG-AMP classification guidelines will incorporate them.
Web resources
CoSeg R package: CRAN-https://cran.r-project.org/web/packages/CoSeg/ index.html.
R-Forge-https://r-forge.r-project.org/projects/coseg/. Online cosegregation analysis tools:
https://www.msbi.nl/cosegregation/default.aspx
